Substance use disorders and neurologic illness

Current Treatment Options in Neurology

Volumn 6, Issue 5, 2004, Pages 421-432

  Davies, Robert D ^a   Thurstone, Christian ^a   Woyewodzic, Kelly ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABIS; COCAINE; DEXTROMETHORPHAN; DICYCLOVERINE; DISULFIRAM; HYPNOTIC SEDATIVE AGENT; IBUPROFEN; KETAMINE; LEVODOPA; LOPERAMIDE; LORAZEPAM; LYSERGIDE; METHADONE; NALTREXONE; NARCOTIC AGENT; NITRITE; OPIATE DERIVATIVE; OXAZEPAM; PHENCYCLIDINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; THIAMINE; UNINDEXED DRUG;

ACNE; ALCOHOL ABUSE; ALCOHOL INTOXICATION; ALCOHOLICS ANONYMOUS; ARTICLE; AWARENESS; BRAIN INJURY; CHOLESTASIS; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC TEST; DIARRHEA; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DROWSINESS; DRUG DEPENDENCE; DRUG MISUSE; DRUG USE; FATIGUE; HEADACHE; HEPATITIS; HUMAN; IMPOTENCE; INSOMNIA; INTOXICATION; LIFESTYLE; LIVER CELL DAMAGE; LIVER TOXICITY; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; MOTIVATION; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NERVOUSNESS; NEURITIS; NEUROLOGIC DISEASE; NEUROLOGY; NONHUMAN; OPTIC NERVE DISEASE; PARKINSON DISEASE; PATIENT COUNSELING; PATIENT REFERRAL; PERIPHERAL NEUROPATHY; PHYSICIAN; POPULATION RESEARCH; PSYCHOSIS; RESPIRATORY TRACT DISEASE; RISK REDUCTION; SEIZURE; SKIN ALLERGY; STOMACH DISEASE; SUBSTANCE ABUSE; TASTE DISORDER; TREATMENT PLANNING; WITHDRAWAL SYNDROME;

EID: 4544383513     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-996-0032-8     Document Type: Article

References (70)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press, 2000.
2. Substance Abuse and Mental Health Services Administration: Results from the 2002 National Survey on Drug Use and Health: National findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2003. Office of Applied Studies, NHSDA Series H-22, DHHS publication no. SMA 03-3836.
3. Regier D, Meyers JK, Kramer M, et al.: The NIMH Epidemiological Catchment Area Study. Arch Gen Psychiatry 1984, 41:934-958.
4. Graham AW: Screening for alcoholism by life-style risk assessment in a community hospital. Arch Intern Med 1991, 151:958-964.
5. Cherpitel CJ: Changes in substance use associated with emergency room and primary care services utilization in the United States general population: 1995-2000. Am J Drug Alcohol Abuse 2003, 29:789-802.
6. Davies MB, Weatherby SJM, Haq N, Ellis SJ: A multiple-sclerosis-like syndrome associated with glue-sniffing. J Royal Soc Med 2000, 93:313-314.
7. Schneck CD, Buzan R: Mood disorders in neurological illness. Curr Treat Options Neurol 2000, 2:151-168.
8. Davies RD, Gabbert SL, Riggs PD: Anxiety disorders in neurological illness. Curr Treat Options Neurol 2001, 3:333-346.
9. Eckardt MJ, File SE, Gessa GL, Grant KA, et al.: The effects of moderate alcohol consumption on the central nervous system. Alcohol Clin Exp Res 1998, 22:998-1040.
10. Mayo-Smith MF: Pharmacological management of alcohol withdrawal. JAMA 1997, 278:144-151.
11. Charness ME: Brain lesions in alcoholics. Alcohol Clin Exp Res 1993, 17:2-11.
12. Gallant DM: Alcoholism and Clinical Psychiatry. New York: Plenum; 1982.
13. Monforte R, Estruch R, Valls-Sole J, et al.: Autonomic and peripheral neuropathies with chronic alcoholism. Arch Neurol 1995, 52:45-51.
14. Edmondson HA: Pathology of alcoholism. Am J Clin Path 1980, 74:725-742.
15. Lopez W, Jeste DV: Movement disorders and substance abuse. Psychiatr Serv 1997, 48:634-636.
16. Estruch R, Sacanella E, Fernandez-Sola J: Natural history of alcoholic myopathy: a 5-year study. Alcohol Clin Exp Res 1998, 22:2023-2028.
17. Bruno A: Cerebrovascular complications of alcohol and sympathomimetic drug abuse. Curr Neurol Neurosci Rep 2003, 3:40-45.
18. NIDA Research Report: Methamphetamine Abuse and Addiction. Bethesda, MD: National Institute on Drug Abuse; 2002. NIDA (NIH) publication no. 02-4210.
19. Flaum M, Schultz SK: When does amphetamine-induced psychosis become schizophrenia? Am J Psychiatry 1996, 153:812-815.
20. NIDA Research Report: Marijuana Abuse. Bethesda, MD: National Institute on Drug Abuse; 2002. NIDA (NIH) publication no. 02-3859.
21. Budney AJ, Moore BA, Vandrey RG, Hughes JR: The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003, 112:393-402.
22. Gruber AJ, Pope HG, Hudson JI, Yergelun-Todd D: Attributes of long-term heavy cannabis users: a case-control study. Psychol Med 2003, 33:1415-1422.
23. Kramer LD, Locke GE, Ogunyemi A, Nelson L: Cocaine-related seizures in adults. Am J Drug Alcohol Abuse 1990, 16:307-317.
24. NIDA Research Report: Cocaine Abuse and Addiction. Bethesda, MD: National Institute on Drug Abuse; 1999. NIDA (NIH) publication no. 99-4342.
25. Domingo P, Martinez E: Parkinsonism associated with long-term cocaine abuse. Arch Intern Med 1997, 157:241.
26. Gowing LR, Henry-Edwards SM, Irvine RJ, Ali RL: The health effects of Ecstasy: a literature review. Drug Alcohol Rev 2002, 21:53-63.
27. NIDA Research Report: MDMA Abuse (Ecstasy). http://www.drugabuse.gov/ResearchReports/MDMA/. 2004.
28. Vollenweider FX, Liechti ME, Gamma A, et al.: Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive Drugs 2002, 34:171-184.
29. Liechti ME, Baumann C, Gamma A, Vollenweider FX: Acute psychological effects of 3,4-Methylendioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacol 2000, 22:513-521.
30. NIDA Research Report: Hallucinogens and Dissociative Drugs. Bethesda, MD: National Institute on Drug Abuse; 2001. NIDA (NIH) publication no. 01-4209.
31. NIDA Research Report: Inhalant Abuse. Bethesda, MD: National Institute on Drug Abuse; 2004. NIDA (NIH) publication no. 00-3818.
32. Dinwiddie SH: Abuse of inhalants: a review. Addiction 1994, 89:925-939.
33. Filley CM, Heaton RK, Rosenberg NL: White matter dementia in chronic toluene abuse. Neurology 1990, 40:532-534.
34. McRae AL, Brady KT, Sonne SC: Alcohol and substance abuse. Med Clin North Am 2001, 85:779-801.
35. Kleber HD. Opioids: Detoxification. In Textbook of Substance Abuse Treatment 1999: edited by Galanter M, Kleber HD.
36. NIDA Research Report: Heroin Abuse. Bethesda, MD: National Institute on Drug Abuse; 2000. NIDA (NIH) publication no. 00-4165.
37. NIDA Infofacts: PCP (Phencyclidine). Accessible at http://www.drugabuse.gov/infofax/pcp.html/.
38. NIDA Research Report: Prescription Drugs: Abuse and Addiction. Bethesda, MD: National Institute on Drug Abuse; 2001. NIDA (NIH) publication no. 01-4881.
39. Smith DE, Wesson DR: Benzodiazepines and Other Sedative-Hypnotics. In Textbook of Substance Abuse Treatment. Washington, DC: American Psychiatric Press; 1999. Edited by Galanter M, Kleber HD.
40. Maloni HW: Pain in multiple sclerosis: an overview of its nature and management. J Neurosci Nurs 2000, 32:139-144.
41. Kirsh KL, Whitcomb LA, Donaghy K, Passik SD: Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study. Clin J Pain 2002, 18(Suppl): S52-S60.
42. Brosseau L, Philippe P, Methot G, et al.: Drug abuse as a risk factor of multiple sclerosis: case-control analysis and a study of heterogeneity. Neuroepidemiol 1993, 12:6-14.
43. Cardoso F, Jankovic J: Movement disorders. Neurol Clin 1993, 11:625-638.
44. Jeste DV, Caligiuri MP, Paulsen JS, et al.: Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psych 1995, 52:756-765.
45. Lucey JL, Dinan TG: Orofacial dyskinesia and the alcohol dependence syndrome. Psychol Med 1992, 22:79-83.
46. Jensen P, Sorensen SA, Fenger K, et al.: A study of psychiatric morbidity in patients with Huntington's disease, their relatives, and controls. Br J Psychiatry 1993, 163:790-797.
47. Lawrence AD, Evans AH, Lees AJ: Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003, 2:595-604.
48. Merims D, Galili-Mosberg R, Melamed E: Is there addiction to levodopa in patients with Parkinsons's disease. Mov Disord 2000, 15:1014-1015.
49. Steiner I, Wirguin I: Levodopa addiction in non-parkinsonian patients. Neurol 2003, 6:1451.
50. Devinsky O: Psychiatric comorbidity in patients with epilepsy: implications for diagnosis and treatment. Epilepsy Behav 2003, 4(Suppl 4):S2-S10.
51. Koppel BS, Samkoff L, Daras M: Relation of cocaine use to seizures and epilepsy. Epilepsia 1996, 37:875-878.
52. Gordon E, Devinsky O: Alcohol and marihuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001, 42:1266-1272.
53. Opeskin K, Harvey AS, Cordner SM, Berkovic SF: Sudden unexpected death in epilepsy in Victoria. J Clin Neurosci 2000, 7:34-37.
54. Hibbard MR, Uysal S, Kepler K, et al.: Axis I psychopathology in individuals with traumatic brain injury. J Head Trauma Rehabil 1998, 13:24-39.
55. Bombardier CH, Rimmele CT, Zintel H: The magnitude and correlates of alcohol and drug use before traumatic brain injury. Arch Phys Med Rehabil 2002, 83:1765-1773.
56. Silver JM, Kramer R, Greenwald S, Weissman M: The association between head injuries and psychiatric disorders: findings from the New Haven NIMH Epidemiologic Catchment Area Study. Brain Injury 2001, 15:935-945.
57. van Reekum R, Cohen T, Wong J: Can traumatic brain injury cause psychiatric disorders? J Neuropsychiatry Clin Neurosci 2000, 12:316-327.
58. Kolakowsky-Hayner SA, Gourley EV III, Kreutzer JS, et al.: Post-injury substance abuse among persons with brain injury and persons with spinal cord injury. Brain Injury 2002, 16:583-592.
59. Crum R: The epidemiology of addictive disorders. In Principles of Addiction Medicine. Edited by Graham A, Schultz T, Wilford BB. Chevy Chase, MD: American Society of Addiction Medicine; 1998:3-16.
60. Brown RL, Rounds LA: Conjoint screening questionnaire for alcohol and drug abuse. Wisc Med J 1995, 94:135-140.
61. Savage SR: Assessment of addiction in pain-treatment settings. Clin J Pain 2002, 18(Suppl 4):S28-S38.
62. Ashman TA, Schwartz ME, Cantor JB, et al.: Screening for substance abuse in individuals with traumatic brain injury. Brain Injury 2004, 18:91-202.
63. American Academy of Pain Medicine, American Pain Society, American Society of Additiodicin Mene: Definitions related to the use of opioids for the treatment of pain. WMJ 2001, 100:28-29.
64. Fiorentine R: After drug treatment: are 12-step programs effective in maintaining abstinence? Am J Drug Alcohol Abuse 1999, 25:93-116.
65. Higgins ST, Budney AJ, Bickel WK, et al.: Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994, 51:568-76.
66. Weissman DE, Haddox JD: Opioid pseudoaddiction: an iatrogenic syndrome. Pain 1989, 36:363-366.
67. Anton RF: Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry 2001, 62(Suppl 20): 11-17.
68. Sanders W, Wildinson C, Phillips M: The impact of a brief motivational intervention with opiate users attending a methadone program. Addiction 1995, 90:415-424.
69. Miller W, Rollnick S: Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press; 1991.
70. Cox WM, Heinemann AW, Miranti SV, et al.: Outcomes of systematic motivational counseling for substance use following traumatic brain injury. J Addictive Dis 2003, 22:93-110.